Delivery Order SPE2DB20D2104-SPE2DB25FMCTQ

Award Date 11/22/24
Potential Completion Date 11/25/24
Potential Value $3.6K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,804.80, is for the delivery of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml, a pharmaceutical product used for diabetes management. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999...
This federal contract award is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml, a pharmaceutical product used for diabetes management. The contract has a firm fixed price of $35,769.87 and a completion date of July 3, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $3,684.32 firm-fixed-price delivery order is for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml, a medication used to treat diabetes. The contract has an ultimate completion date of August 2, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $31,718.46 delivery order contract is for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml, a prescription medication used for diabetes management. The contract has a firm fixed price structure and a completion date of December 2, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,759.96, is for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml, a medication used to treat diabetes. The contract is a delivery order with a firm fixed price, and the ultimate completion date is February 26, 2025. The contract does not have a set-aside designation, indicating open competition....
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, to provide Ozempic 1 mg/dose (4 mg/3 ml) 3 ml, a diabetes medication. The contract has a ceiling value of $10,126.40 and an ultimate completion date of January 13, 2025. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $10,449.36, is for the delivery of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml, a medication used to treat diabetes. The contract has a completion date of December 12, 2023 and is a firm fixed-price delivery order. This award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen...
This federal contract award, valued at $26,258.36, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for the delivery of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml, a prescription medication used to treat type 2 diabetes. The contract is a Firm Fixed Price Delivery Order with an ultimate completion date of October 30, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract...
This federal contract award, valued at $7,046.79, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml, a medication used in the management of diabetes. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999 and...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,910.56, is for the delivery of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml, a medication used to treat diabetes. The contract has a completion date of November 18, 2024 and is a firm fixed-price delivery order. The contract is not designated as a set-aside. AmerisourceBergen holds a significant...
  • SPE2DB20D2104
    Indefinite Delivery Contract
  • SPE2DB20D2104-SPE2DB25FMCTQ
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, to provide Ozempic 1 mg/dose (4 mg/3 ml) 3 ml, a medication for diabetes management. The contract, valued at $3,553.25, is a firm fixed-price delivery order with a completion date of November 25, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

Generated 2/21/25, 9:39 AM